Toronto, Ontario – May 30, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s unaudited 1Q2022 condensed interim consolidated Financial Statements (“Financial Statements”). Financial Highlights: For the three- month period ended March 31st: Audited Consolidated Statements of Operations             In Canadian Dollars     2022 2021 % Change  Revenue       Canada 179,145 104,406 72% United States 32,517         20,377 60% Total Revenue 211,662 124,783 70%         Cost of Sales 120,430 74,463 62% Gross Margin 91,232 50,320 81% Gross Margin as a percentage of sales 43% 40%           Operating Expenses       Selling Expenses 87,640 95,780 -8% Administrative Expenses 418,087 418,454 1% Research and Development Expenses – CLT Division 72,832 54,616 33% Research and Development Expenses … Read More

Toronto, Ontario – April 29, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2021 financial statements. Financial Highlights: For the years ended December 31st: Audited Consolidated Statements of Operations             In Canadian Dollars    2021 2020 % Change   Revenue       Canada 697,727 815,159 -14% United States 69,725 87,923 -21% International 13,189 26,040 -49% Total Revenue 780,641 929,122 -16%         Cost of Sales 470,698 659,442 -29% Gross Margin 309,943 269,680 15% Gross Margin as a percentage of sales 40% 29%           Operating Expenses       Selling Expenses 363,886 447,882 -19% Administrative Expenses 1,562,867 2,070,261 -25% Research and Development Expenses – CLT Division 308,708 … Read More

Toronto, Ontario – April 5, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) 1 and their associated drug formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, has provided an update on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). As previously announced, Theralase® successfully completed a Phase Ib NMIBC Clinical Study (“Study I”), which enrolled and provided the primary study treatment, at the therapeutic dose, for 3 patients.  To date, Study II has enrolled and provided the primary study treatment for 35 patients, which when combined with the Study I data, leads to a total of 38 patients, who have received at a minimum, the primary study treatment. Study II Clinical Study Data: Assessment (Days) Complete Response (“CR”) … Read More

Toronto, Ontario – February 7, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds1 (“PDC”) and their associated drug formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 (“COVID-19”) vaccine.  In August 2020, Theralase® reported that it had executed a Sponsored Research Agreement (“SRA”) with the University of Manitoba (“UM”) medical microbiology department to commence research and development of a Canadian-made vaccine, utilizing Theralase®’s patented and proprietary PDC, TLD-1433.  In November 2020, Theralase® reported that, UM was able to demonstrate that TLD-1433 was effective in the rapid destruction of various viruses, including: H1N1 Influenza, Zika and a Biological Safety Level (“BSL”)-2 coronavirus at low nanomolar (“nM”) concentrations.  All these enveloped viruses are similar in structure to … Read More

Toronto, Ontario – December 9, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that the Company has expanded its Intellectual Property (“IP”) portfolio. Theralase® has recently been granted an Indian patent for, “Metal-Based Coordination Complexes as Photodynamic Compounds and their Use”. This patent encompasses numerous Theralase®’s PDCs destined for the Indian market; most importantly, TLD-1433, which is currently under clinical investigation in a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study, being conducted in Canada and the United States.    The Mechanism of Action (“MOA”) of the patented Theralase® PDCs involves localization of the PDC inside the cancer cells of interest and then activating it by laser … Read More

Toronto, Ontario – November 29, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses has released the Company’s unaudited 3Q2021 condensed interim consolidated Financial Statements (“Financial Statements”), which provides financial information on the previous fiscal quarter and the quarterly Newsletter (“Newsletter”) which provides an interim clinical data analysis on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) clinical study (“Study II”). The Financial Statements can be found on the Company’s Website at www.theralase.com/financial-filings/ The Newsletter can be found on the Company’s website at www.theralase.com/quarterly-newsletters/ Highlights from the Newsletter: Leadership Transition Effective October 25, 2021, Vera Madzarevic, Ph.D. assumed the role of Director of Clinical Development and Quality … Read More

Toronto, Ontario – November 15, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the following leadership reorganization: Effective November 15, 2021, Dr. Arkady Mandel, M.D., Ph.D., D.Sc., who is currently the Chief Scientific Officer (“CSO”) of the Company, will assume the role of Interim Chief Executive Officer (“CEO”), replacing Mr. John Trikola in the role of Interim CEO of the Company. Mr. Trikola has agreed to resign from his positions as the Chief Operating Officer and Interim CEO of the Company effective immediately, as a result of certain facts that have come to the Company’s attention concerning Mr. Trikola’s background that the Company’s vetting process failed to detect. The Company is currently taking steps to improve its vetting process for incoming officers … Read More

Toronto, Ontario – August 30, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses has released the Company’s unaudited Q22021 condensed interim consolidated financial statements and Quarterly Newsletter (“Newsletter”) which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). The Financial Statements can be found on the Company’s Website at www.theralase.com/financial-filings/ The Newsletter can be found on the Company’s website at www.theralase.com/quarterly-newsletters/ Highlights from the Newsletter: Leadership Transition Effective August 23, 2021, John Trikola assumed the role of Chief Operating Officer (“COO”) and Interim CEO for the Company. John brings over 25 years of technology … Read More

Toronto, Ontario – August 19, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the departure of its Chief Executive Officer (“CEO”),  Shawn Shirazi effective August 20, 2021. Effective August 23, 2021, John Trikola will assume the role of Chief Operating Officer (“COO”) and Interim CEO for the Company.  John brings over 25 years of technology experience working with companies ranging from startups to global Fortune 500 companies.  Most recently, John was the president of Gardner Ross Corp., where he provided turnaround and restructuring engagements to various companies in the technology, manufacturing, and retail sectors.  In addition to his senior management roles, John currently serves as a Board Director for Waypoint Centre for Mental Health Care and has served on the Board of Directors … Read More

Toronto, Ontario – June 11, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of innovative Anti-Cancer Therapy (“ACT”) technologies  intended to safely and effectively destroy various cancers, bacteria and viruses, while preserving patient Quality Of Life (“QOL”) announced today the launch of the seventh US-based Clinical Study Site (“CSS”); specifically, the University of Chicago Medicine (“UChicago Medicine”). UChicago Medicine has successfully received Institutional Review Board (“IRB”) approval allowing them to commence enrollment and treatment of patients in Theralase®’s pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). Study II is focused on the enrollment and treatment of approximately 100 to 125 patients, who have been previously diagnosed with Bacillus Calmette Guérin (“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG therapy (“Study II“). The Company has successfully launched five CSSs in Canada … Read More